Veru, Inc. (VERU)
2.74
+0.05
(+1.86%)
USD |
NASDAQ |
Sep 02, 16:00
2.74
0.00 (0.00%)
After-Hours: 19:31
Veru Research and Development Expense (TTM) : 11.76M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.76M |
| March 31, 2026 | 10.43M |
| December 31, 2025 | 11.22M |
| September 30, 2025 | 15.59M |
| June 30, 2025 | 15.96M |
| March 31, 2025 | 17.79M |
| December 31, 2024 | 16.84M |
| September 30, 2024 | 12.78M |
| June 30, 2024 | 16.16M |
| March 31, 2024 | 14.24M |
| December 31, 2023 | 29.11M |
| September 30, 2023 | 48.07M |
| June 30, 2023 | 68.29M |
| March 31, 2023 | 83.50M |
| December 31, 2022 | 81.18M |
| September 30, 2022 | 70.65M |
| June 30, 2022 | 52.01M |
| March 31, 2022 | 45.07M |
| December 31, 2021 | 37.10M |
| September 30, 2021 | 32.69M |
| June 30, 2021 | 27.71M |
| March 31, 2021 | 20.96M |
| December 31, 2020 | 17.31M |
| September 30, 2020 | 16.94M |
| June 30, 2020 | 17.27M |
| Date | Value |
|---|---|
| March 31, 2020 | 17.70M |
| December 31, 2019 | 16.68M |
| September 30, 2019 | 13.74M |
| June 30, 2019 | 13.17M |
| March 31, 2019 | 12.09M |
| December 31, 2018 | 11.25M |
| September 30, 2018 | 10.85M |
| June 30, 2018 | 8.864M |
| March 31, 2018 | 5.503M |
| December 31, 2017 | 4.864M |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ANI Pharmaceuticals, Inc. | 49.91M |
| Corcept Therapeutics, Inc. | 253.86M |
| Johnson & Johnson | 15.06B |
| Eli Lilly & Co. | 14.60B |
| Lexicon Pharmaceuticals, Inc. | 59.79M |